Menopause
Also known as: Change of life
Methodology & AI Transparency ⓘ
Menopause Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is menopause? Menopause is the time in your life when you stop having your period and can no longer get pregnant.
- 2 Real-world patient consensus: Mapped to Menopause, Perimenopause & Hormone Therapy under ICD-10-CM N95.4 for Menopause clinical workups.
- 3 Typical cash cost range: Clinicians assessing Menopause focus on falling 17-beta-estradiol [Menopause N95.4] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Menopause monitoring tracks 17-Beta Estradiol & in Menopause (N95.4: FSH (Contextual)) toward Symptom-guided physiological target (N95.4).
Ask our AI Specialists anything about Menopause
What Is Menopause?
What is menopause? Menopause is the time in your life when you stop having your period and can no longer get pregnant. You have reached menopause when you have not had a period for 12 months. The time leading up to menopause is called the menopausal transition, or perimenopause. This transition usually begins when you are in your 40s, but sometimes it can start earlier. It can last for several years. The most common age for reaching menopause is between 45 and 55 years old. What is early and premature menopause? Early and premature menopause happens when your ovaries stop making hormones and your periods stop at a younger age than usual.
Pathophysiology, Underlying Causes & Clinical Presentation
In Menopause (N95.4), physiological disruption stems from falling 17-beta-estradiol [Menopause N95.4], Cross-referenced with NIH MeSH (Menopause), informing Menopause, Perimenopause & Hormone Therapy protocols that track DEXA Bone Density in Menopause (N95.4: & Fasting ApoB) (T-Score > -1.0; ApoB < 75 mg/dL (N95.4)).
Common Symptoms & Clinical Signs
- • A family history of early or premature menopause
- • Certain health conditions
- • Presentation of Menopause (N95.4): genitourinary dryness, urinary in Menopause (N95.4: urgency, or discomfort)
- • Secondary Menopause clinical sign: midsection body-composition shift, in Menopause (N95.4: joint stiffness, and)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Menopause Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N95.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Menopause, Perimenopause & Hormone Therapy | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 17-Beta Estradiol & in Menopause (N95.4: FSH (Contextual)) | Symptom-guided physiological target (N95.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Bone Density in Menopause (N95.4: & Fasting ApoB) | T-Score > -1.0; ApoB < 75 mg/dL (N95.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & HbA1c in Menopause (N95.4: Midlife Panel) | TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (N95.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Menopause
Treatment selection for Menopause depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Menopause)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due: What a 952-Participant Study Found Pooled data confirm the safety and tolerability of fezolinetant over 52 weeks. Advances in therapy • 2025-02-15 • Meta-Analysis | N = 952 | 97/100 | PMID 39739195 ↗ |
| New Insights on Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause:: What a 1,022-Participant Study Found None of the intrinsic and extrinsic factors analyzed substantially reduced the efficacy response to fezolinetant in SKYLIGHT 1 and 2. Menopause (New York, N.Y.) • 2024-04-01 • Phase III Randomized Trial | N = 1,022 | 96/100 | PMID 38517210 ↗ |
| New Insights on Validation and Application of Thresholds to Define Meaningful Change in Vasomotor: What a 1,022-Participant Study Found PGI-C VMS is sensitive to change and correlates with VMS frequency: a reduction of approximately six VMS episodes per day from baseline to week 12 was meaningful at the individual patient level. Advances in therapy • 2024-07-15 • Phase III Randomized Trial | N = 1,022 | 96/100 | PMID 38775925 ↗ |
| New Insights on Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable: What a 1,022-Participant Study Found This pooled analysis demonstrated efficacy of fezolinetant vs. Current medical research and opinion • 2025-02-15 • Randomized Controlled Trial | N = 1,022 | 96/100 | PMID 40044127 ↗ |
| New Insights on Effect of fezolinetant on sleep disturbance and impairment during treatment of: What a 1,022-Participant Study Found Fezolinetant had a beneficial effect on four measures of sleep disturbance and impairment following treatment for VMS. Maturitas • 2024-08-15 • Phase III Randomized Trial | N = 1,022 | 96/100 | PMID 38749864 ↗ |
Menopause Patient Community & “People Like Me” Threads
Filter Menopause community threads and patient logs by age, biological sex, dosage, and treatment duration.